AEterna Zentaris to Present at Orion Healthcare Conference September 13 in Toronto
September 07 2004 - 8:32AM
PR Newswire (US)
AEterna Zentaris to Present at Orion Healthcare Conference
September 13 in Toronto QUEBEC CITY, Sept. 7 /PRNewswire-FirstCall/
-- AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) announced today
that Gilles Gagnon, President and Chief Executive Officer of the
Company, will present a corporate update at Orion Securities' 9th
Annual Healthcare Conference, at 9:00 a.m. ET, on Monday, September
13, 2004, which will be held at the King Edward Hotel in Toronto.
About AEterna Zentaris Inc. AEterna Zentaris Inc. is a
biopharmaceutical company focused in oncology and endocrine
therapy. Its extensive portfolio, from drug discovery to marketed
products, includes perifosine, an orally-active AKT inhibitor in
several Phase II trials for multiple cancers, and cetrorelix, an
LHRH antagonist already marketed for in vitro fertilization under
the brand name Cetrotide(R), and also in advanced clinical
development for the treatment of uterine myoma, endometriosis and
benign prostatic hyperplasia (BPH). AEterna Zentaris also owns 62%
of Atrium Biotechnologies Inc., which develops, distributes and
markets active ingredients, specialty fine chemicals, cosmetic and
nutritional products for the cosmetics, chemical, pharmaceutical
and nutritional industries. News releases and additional
information about AEterna Zentaris are available on its new Web
site http://www.aeternazentaris.com/ . Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related
to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned not to rely
on these forward-looking statements. The Company does not undertake
to update these forward- looking statements. DATASOURCE: AETERNA
ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA
CONTACT: Media Relations, Paul Burroughs, (418) 652-8525, ext. 406,
; U.S. Investor Relations, Lippert/Heilshorn & Associates, Kim
Golodetz, (212) 838-3777, ; Investor Relations, Jacques Raymond,
(418) 652-8525 ext. 360, ; Europe, Matthias Seeber, +49 69 42602
3425, ; To request a free copy of this organization's annual
report, please go to http://www.newswire.ca/ and click on
reports@cnw.
Copyright